Sjögren's syndrome - Can we stratify the lymphoma risk?;Sjögren-syndrom - Können wir das lymphomrisiko stratifizieren?

Aktuelle Rheumatologie

Volumn 30, Issue 1, 2005, Pages 46-49

  Hansen, Arne ^a   Hoffmann, A ^a   Dorner T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemotherapy; Immunotherapy; Low grade Non Hodgkin's lymphoma; Sj gren's syndrome

Indexed keywords

ARTICLE; B LYMPHOCYTE; CHEMOTHERAPY; CHRONIC INFLAMMATION; CRYOGLOBULINEMIA; DIFFERENTIAL DIAGNOSIS; GAMMOPATHY; HUMAN; IMMUNOELECTROPHORESIS; IMMUNOTHERAPY; LYMPHADENOPATHY; LYMPHOMA; NONHODGKIN LYMPHOMA; RISK ASSESSMENT; SJOEGREN SYNDROME; STATISTICAL SIGNIFICANCE;

EID: 14744280573     PISSN: 0341051X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-857934     Document Type: Article

References (30)

1. Jonsson R, Haga HJ, Gordon T. Sjögren's syndrome. In: Koopman WJ (Hrsg). Arthritis and allied conditions - a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams and Wilkins, 2001: 1736-1759
2. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002; 46: 741-747
3. Kassan SS, Thomas TL, Moutsopoulos HM et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888-892
4. Voulgarelis M, Dafni UG, Isenberg DA et al. Malignant lymphoma in primary Sjögren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's syndrome. Arthritis Rheum 1999; 42: 1765-1772
5. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren's syndrome: new clinical and theurapeutic concepts. Ann Rheum Dis 2004 Oct 21; [Epub ahead of print] 10.1136/and 2004. 025676; ARD Online First
6. Jaffe ES. Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis. Mod Pathol 2002; 15: 255-263
7. Harris NL. Lymphoid proliferations of the salivary glands. Am J Clin Pathol 1999; 111 (1 Suppl 1): S94-103
8. Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue type lymphomas. Blood 1997; 89: 3335-3344
9. Gasparotto D, De Vita S, De Re V et al. Extrasalivary lymphoma development in Sjögren's syndrome. Clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum 2003; 48: 3181-3186
10. Martin T, Weber JC, Levallois H et al. Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 2000; 43: 908-916
11. Isaacson PG, Du MQ. MALT-lymphoma: from morphology to molecules. Nature Reviews 2004; 4: 644-653
12. Inagaki H, Chan JK, Ng et al. Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features. Am J Pathol 2002; 160: 1435-1443
13. Tonami H, Matoba M, Kuginuki Y et al. Clinical and imaging findings of lymphoma in patients with Sjögren's syndrome. J Comput Assist Tomogr 2003; 27: 517-524
14. Carbone A, Gloghini A, Ferlito A. Pathological features of lymphoid proliferations of the salivary glands: lymphoepithelial sialadenitis versus low-grade B-cell lymphoma of the malt type. Ann Otol Rhinol Laryngol 2000; 109: 1170-1175
15. De Vita S, Boiocchi M, Sorrentino D et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. Arthritis Rheum 1997; 40: 318-331
16. Anaya JM, McGuff HS, Banks PM et al. Clinicopathological factors relating malignant lymphoma with Sjögren's syndrome. Semin Arthritis Rheum 1996; 25: 337-346
17. Tzioufas AG, Boumba DS, Skopouli FN et al. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996; 39: 767-772
18. Shokri F, Mageed RA, Maziak BR et al. Lymphoproliferation in primary Sjögren's syndrome. Athritis Rheum 1993; 36: 1128-1136
19. Hansen A, Lipsky PE, Dörner T. New concepts in the pathogenesis of Sjögren's syndrome: many questions, fewer answers. Curr Opin Rheumatol 2003; 15: 563-570
20. Hansen A, Odendahl M, Reiter K et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 2002; 46: 2160-2171
21. Dong HY, Shahsafaei A, Dorfman DM. CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naive B cells. Leuk Lymphoma 2002; 43: 1855-1858
22. Yonetsu K, Takagi Y, Sumi M et al. Sonography as a replacement for sialography for the diagnosis of salivary glands affected by Sjögren's syndrome. Ann Rheum Dis 2002; 61: 276-277 [Letter]
23. Queneau PE, Helg C, Brundler MA et al. Diagnosis of a gastric mucosa-associated lymphoid tissue lymphoma by endoscopic ultrasonography-guided biopsies in a patient with a parotid gland localization. Scand J Gastroenterol 2002; 37: 493-496
24. Zinzani PL. Traditional treatment approaches in B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44(Suppl 4): S6-14
25. Seymour JF. New treatment approaches to indolent non-Hodgkin's lymphoma. Semin Oncol 2004; 31 (1 Suppl 2): 27-32
26. Gustavsson A, Osterman B, Cavallin-Stahl E. A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol 2003; 42: 605-619
27. Buske C, Dreyling M, Unterhalt M et al. [Monoclonal antibodies in the treatment of malignant lymphoma]. Internist (Berl) 2004; 45: 1370-1377
28. Trumper L, Glass B, Hartmann F et al. [New diagnostic and therapeutic strategies for aggressive lymphomas]. Dtsch Med Wochenschr 2004; 129: 2113-2117
29. Ghobrial I, Witzig T. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. Oncology 2004; 18: 623-630; discussion 633-634, 637-638, 640
30. Shih WJ, Ghesani N, Hongming Z et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjögren's syndrome: before and after anti-CD20 antibody rituximab therapy. Clin Nucl Med 2002; 27: 142-143